Advertisement

Hemodialysis Access: Fundamentals and Advanced Management, the Experience in Taiwan

  • Shang-Feng Yang
  • Kuo-Hua Lee
  • Chih-Ching LinEmail author
Chapter

Abstract

Because of the high availability and easy accessibility of medical service, hemodialysis (HD) continues to be the most commonly utilized renal replacement therapy in Taiwan. Among the 67,665 prevalent ESRD patients, more than 60,000 of patients (89.7 %) undergoing in-center HD twice to three times per week. This chapter discusses the management of ESRD and the hemodialysis experience in Taiwan.

Keywords

Taiwan hemodialysis ESRD in Taiwan 

References

  1. 1.
    Yen-Chung Lin C-YH, Chih-Chin Kao, Tzen-Wen Chen, His-Hsien Chen C-CH, Mai-Szu WU. Incidence and prevalence of ESRD in Taiwan Renal Registry Data System (TWRDS): 2005–2012. Acta Nephrol. 2014;28:65–8.Google Scholar
  2. 2.
    Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl. 2015;5:2–7.CrossRefGoogle Scholar
  3. 3.
    財團法人國家衛生研究院. 台灣慢性腎病診療指引. 2015.Google Scholar
  4. 4.
    Chen HS, Cheng CT, Hou CC, Liou HH, Lim PS. Survival and other clinical outcomes of maintenance hemodialysis patients in Taiwan: a 5-year multicenter follow-up study. Hemodial Int. 2014;18:799–808.CrossRefPubMedGoogle Scholar
  5. 5.
    Ng YY, Hung YN, Wu SC, Ko PJ. Characteristics and 3-year mortality and infection rates among incident hemodialysis patients with a permanent catheter undergoing a first vascular access conversion. Clin Exp Nephrol. 2014;18:329–38.CrossRefPubMedGoogle Scholar
  6. 6.
    Smith GE, Gohil R, Chetter IC. Factors affecting the patency of arteriovenous fistulas for dialysis access. J Vasc Surg. 2012;55:849–55.CrossRefPubMedGoogle Scholar
  7. 7.
    Ng YY, Wu SC, Hung YN, Ko PJ. Effect of demographic characteristics and timing of vascular access maturation on patency in Chinese incident haemodialysis patients. Nephrol Dial Transplant. 2009;24:3447–53.CrossRefPubMedGoogle Scholar
  8. 8.
    Chen SC, Chang JM, Hwang SJ, et al. Significant correlation between ankle-brachial index and vascular access failure in hemodialysis patients. Clini J Am Soc Nephrol. 2009;4:128–34.CrossRefGoogle Scholar
  9. 9.
    Chou CY, Liu JH, Kuo HL, et al. The association between pulse pressure and vascular access thrombosis in chronic hemodialysis patients. Hypertens Res. 2009;32:712–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014;25:1897–907.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wu CC, Hsieh MY, Hung SC, et al. Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts. J Am Soc Nephrol. 2015;27:1254–64.CrossRefPubMedGoogle Scholar
  12. 12.
    Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Wu CC, Wen SC, Yang CW, Pu SY, Tsai KC, Chen JW. Plasma ADMA predicts restenosis of arteriovenous fistula. J Am Soc Nephrol. 2009;20:213–22.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wu CC, Huang PH, Lai CL, Leu HB, Chen JW, Lin SJ. The impact of endothelial progenitor cells on restenosis after percutaneous angioplasty of hemodialysis vascular access. PLoS One. 2014;9:e101058.Google Scholar
  15. 15.
    Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–39.CrossRefPubMedGoogle Scholar
  16. 16.
    Lin CC, Yang WC, Chung MY, Lee PC. Functional polymorphisms in matrix metalloproteinases-1, −3, −9 are associated with arteriovenous fistula patency in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1805–14.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Exner M, Schillinger M, Minar E, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther. 2001;8:433–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Kaneda H, Ohno M, Taguchi J, et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol. 2002;22:1680–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Schillinger M, Exner M, Mlekusch W, et al. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb Res. 2002;106:131–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Lin CC, Yang WC, Lin SJ, et al. Length polymorphism in heme oxygenase-1 is associated with arteriovenous fistula patency in hemodialysis patients. Kidney Int. 2006;69:165–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Osborn G, Escofet X, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2008;(4):CD002786.Google Scholar
  22. 22.
    Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299:2164–71.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Capon A, Mordon S. Can thermal lasers promote skin wound healing? Am J Clin Dermatol. 2003;4:1–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Yu SY, Chiu JH, Yang SD, Hsu YC, Lui WY, Wu CW. Biological effect of far-infrared therapy on increasing skin microcirculation in rats. Photodermatol Photoimmunol Photomed. 2006;22:78–86.CrossRefPubMedGoogle Scholar
  25. 25.
    Akasaki Y, Miyata M, Eto H, et al. Repeated thermal therapy up-regulates endothelial nitric oxide synthase and augments angiogenesis in a mouse model of hindlimb ischemia. Circ J. 2006;70:463–70.CrossRefPubMedGoogle Scholar
  26. 26.
    Imamura M, Biro S, Kihara T, et al. Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. J Am Coll Cardiol. 2001;38:1083–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Ikeda Y, Biro S, Kamogawa Y, et al. Repeated sauna therapy increases arterial endothelial nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. Circ J. 2005;69:722–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Kihara T, Biro S, Ikeda Y, et al. Effects of repeated sauna treatment on ventricular arrhythmias in patients with chronic heart failure. Circ J. 2004;68:1146–51.CrossRefPubMedGoogle Scholar
  29. 29.
    Lin CC, Chang CF, Lai MY, Chen TW, Lee PC, Yang WC. Far-infrared therapy: a novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. J Am Soc Nephrol. 2007;18:985–92.CrossRefPubMedGoogle Scholar
  30. 30.
    Lin CC, Liu XM, Peyton K, et al. Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. Arterioscler Thromb Vasc Biol. 2008;28:739–45.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Chen YH, Chau LY, Lin MW, et al. Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J. 2004;25:39–47.CrossRefPubMedGoogle Scholar
  32. 32.
    Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006;86:583–650.CrossRefPubMedGoogle Scholar
  33. 33.
    Durante W. Heme oxygenase-1 in growth control and its clinical application to vascular disease. J Cell Physiol. 2003;195:373–82.CrossRefPubMedGoogle Scholar
  34. 34.
    Durante W, Johnson FK, Johnson RA. Role of carbon monoxide in cardiovascular function. J Cell Mol Med. 2006;10:672–86.CrossRefPubMedGoogle Scholar
  35. 35.
    Lin CC, Chung MY, Yang WC, Lin SJ, Lee PC. Length polymorphisms of heme oxygenase-1 determine the effect of far-infrared therapy on the function of arteriovenous fistula in hemodialysis patients: a novel physicogenomic study. Nephrol Dialy Transplant. 2013;28:1284–93.CrossRefGoogle Scholar
  36. 36.
    Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. Am J Kidney Dis. 2013;62:304–11.CrossRefPubMedGoogle Scholar
  37. 37.
    Lai CC, Fang HC, Mar GY, Liou JC, Tseng CJ, Liu CP. Post-angioplasty far infrared radiation therapy improves 1-year angioplasty-free hemodialysis access patency of recurrent obstructive lesions. Eur J Vasc Endovasc Surg. 2013;46:726–32.CrossRefPubMedGoogle Scholar
  38. 38.
    Wu LC, Lin MY, Hsieh CC, et al. Planned creation of vascular access saves medical expenses for incident dialysis patients. Kaohsiung J Med Sci. 2009;25:521–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Shang-Feng Yang
    • 1
    • 3
  • Kuo-Hua Lee
    • 2
    • 3
  • Chih-Ching Lin
    • 2
    • 3
    Email author
  1. 1.Division of Nephrology, Department of MedicineCheng Hsin General HospitalTaipeiRepublic of China
  2. 2.Division of Nephrology, Department of MedicineTaipei Veterans General HospitalTaipeiRepublic of China
  3. 3.School of MedicineNational Yang Ming UniversityTaipeiRepublic of China

Personalised recommendations